Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 17/20 | 1.00 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19346827 | 1.00 | PRMT5 (1.00) | PRMT5SMYD3IDH1 | |
| SCHEMBL22449430 | 1.00 | PRMT5 (1.00) | PRMT5SMYD3IDH1 | |
| Hydrochloric Acid SCHEMBL22449429 | 0.99 | PRMT5 (0.98) | PRMT5SMYD3IDH1 | |
| Hydrochloric Acid SCHEMBL19329416 | 0.99 | PRMT5 (0.98) | PRMT5SMYD3IDH1 | |
| Hydrochloric Acid SCHEMBL19329418 | 0.99 | PRMT5 (0.98) | PRMT5SMYD3IDH1 | |
| SCHEMBL22449417 | 0.94 | PRMT5 (1.00) | PRMT5SMYD3IDH1 | |
| SCHEMBL19346800 | 0.94 | PRMT5 (1.00) | PRMT5SMYD3IDH1 | |
| SCHEMBL22449416 | 0.94 | PRMT5 (1.00) | PRMT5SMYD3IDH1 | |
| SCHEMBL22730106 | 0.93 | PRMT5 (0.90) | PRMT5SMYD3IDH1 | |
| SCHEMBL22730104 | 0.93 | PRMT5 (0.90) | PRMT5SMYD3IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787434-B2 | Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY, LTD (AU) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787434-B2 | Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies | HBB, HBG2, HBZ | PRMT5 1971/4885SMYD3 646/4885IDH1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.